BIOHIT OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.02 EUR | +1.25% |
|
-1.46% | +7.16% |
| Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
| Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 47% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
Ratings chart - Surperformance
Sector: Office Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +7.16% | 32.72M | - | ||
| +7.13% | 7.91B | B- | ||
| -3.15% | 4.66B | B | ||
| -9.18% | 2.84B | - | ||
| +1.11% | 2.03B | - | ||
| -26.56% | 1.12B | - | ||
| -11.09% | 816M | C+ | ||
| -13.49% | 755M | - | ||
| -22.71% | 759M | - | ||
| -56.85% | 682M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIOBV Stock
- Ratings Biohit Oyj
